摘要
NSCLC是最常见的恶性肿瘤之一,化学治疗对NSCLC的疗效已经达到平台期,但本世纪初靶向治疗研究的突破性进展为人们带来了新的希望。根据靶点的不同将靶向药物分为:以EGFR为靶点、以VEGF为靶点及多靶点药物等,本文将介绍吉非替尼、厄洛替尼、西妥昔单抗等代表药物在NSCLC靶向一线、二线及维持治疗中的新进展。
Non-Small-Cell Lung Carcinoma （NSCLC） is one of the most common malignant tumors, and conventional chemotherapy exhibits limitations in treating the lung disease. However, the breakthrough in targeted nanoparticles for cancer therapy in the twenty-first century offers profound potentials and great hopes in addressing this challenge. Depending on different targeting molecules, the target drug system is classified into EGFR-based, VEGF-based and multi-based. In this article, we review the latest advancement of the emerging technology in the first- and second-line treatment as well as maintaining treatment in lung cancers, with a highlight on representatives of some promising classes of drugs such as Gefmitib, Angiostatin and Cetuximab.
出处
《现代生物医学进展》
CAS
2011年第16期3183-3186,共4页
Progress in Modern Biomedicine
